Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients [3]

AIDS

Volumn 19, Issue 11, 2005, Pages 1240-1241

  Konishi, Mitsuru ^a   Takahashi, Ken ^a   Yoshimoto, Eiichiro ^a   Uno, Kenji ^a   Kasahara, Kei ^a   Mikasa, Keiichi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DEOXYPYRIDINOLINE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEINASE INHIBITOR;

ADULT; BONE DENSITOMETRY; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPODYSTROPHY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 23044473793     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000176231.24652.02     Document Type: Letter

References (5)

1. Glesby MJ. Bone disorders in human immunodeficiency virus infection. Clin Infect Dis 2003; 37 (Suppl. 2):S91-S95.
2. Jones DH, Kong Y-Y, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002; 61:ii32-ii39.
3. D'Amelio P, Grimaldi A, Pescarmona GP, Tamone C, Roato I, Isaia G. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J 2005; 19:410-412.
4. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via RANKL secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003; 278:48251-48258.
5. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2004; 150:67-78.